Uncommon cytogenetic abnormalities identifying high-risk acute myeloid leukemia in children

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Zwaan CM, Kolb EA, Reinhardt D et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J. Clin. Oncol. 33(27), 2949–2962 (2015).
  Medline CASGoogle Scholar
• 2. Rasche M, Zimmermann M, Borschel L et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 32(10), 2167–2177 (2018).
  MedlineGoogle Scholar
• 3. Pession A, Masetti R, Rizzari C et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 122(2), 170–178 (2013).
  Medline CASGoogle Scholar
• 4. Buldini B, Maurer-Granofszky M, Varotto E, Dworzak MN. Flow-cytometric monitoring of minimal residual disease in pediatric patients with acute myeloid leukemia: recent advances and future strategies. Front. Pediatr. 11(7), 412 (2019).
  Google Scholar
• 5. Buldini B, Rizzati F, Masetti R et al. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. Br. J. Haematol. 177(1), 116–126 (2017).
  MedlineGoogle Scholar
• 6. Pession A, Lonetti A, Bertuccio S, Locatelli F, Masetti R. Targeting hedgehog pathway in pediatric acute myeloid leukemia: challenges and opportunities. Expert Opin. Ther. Targets 23(2), 87–91 (2019).
  MedlineGoogle Scholar
• 7. Bolouri H, Farrar JE, Triche T et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat. Med. 24(1), 103–112 (2018).
  Medline CASGoogle Scholar
• 8. de Rooij JD, Masetti R, den van Heuvel-eibrink MM et al. Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. Blood 127(26), 3424–3431 (2016).
  MedlineGoogle Scholar
• 9. de Rooij JD, Branstetter C, Ma J et al. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nat. Genet. 74(1), 27–34 (2017).
  Google Scholar
• 10. Masetti R, Guidi V, Ronchini L, Bertuccio NS, Locatelli F, Pession A. The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children. Crit. Rev. Oncol. Hematol. 138, 132–138 (2019).
  MedlineGoogle Scholar
• 11. Inaba H, Zhou Y, Abla O et al. Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. Blood 126(13), 1575–1584 (2015).
  Medline CASGoogle Scholar
• 12. Masetti R, Pigazzi M, Togni M et al. CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood 121(17), 3469–3472 (2013). • Demonstrated for the first time that CBFA2T3-GLIS2 is a common fusion gene identified in 8.4% of cytogenetically normal acute myeloid leukemia (AML) and does not exclusively characterize pediatric non-Down syndrome acute megakaryoblastic leukemia (non-DS-AMKL).
  Medline CASGoogle Scholar
• 13. de Rooij JD, Hollink I, Arentsen-peters S et al. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia 27(12), 2280–2288 (2013). • First study identifying JARID1A (aka KDM5A) as a partner of NUP98 in AMKL pediatric patients.
  MedlineGoogle Scholar
• 14. Schwartz S, Jiji R, Kerman S, Meekins J, Cohen MM. Translocation (6;9)(p23;q34) in acute nonlymphocytic leukemia. Cancer Genet. Cytogenet. 18(4), 133–138 (1983).
  Google Scholar
• 15. Slovak M, Gundacker H, Bloomfield CD, Heerema NA. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ´poor prognosis´ myeloid malignancies. Leukemia 20(7), 1295–1297 (2006).
  Medline CASGoogle Scholar
• 16. Tarlock K, Todd A, Moraleda PP et al. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group. Br. J. Haematol. 166(2), 254–259 (2014). •• Provides conclusive data that pediatric AML patients with t(6;9) are at a high risk of relapse and have a poor outcome independent of the presence of FLT3-ITD; patients with t(6;9) who receive hematopoietic stem cell transplantation (HSCT) have a more favorable outcome.
  MedlineGoogle Scholar
• 17. Sandahl JD, Coenen EA, Forestier E et al. t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. Haematologica 99(5), 865–872 (2014). •• Provides conclusive data that pediatric AML patients with t(6;9) are at a high risk of relapse and have a poor outcome independent of the presence of FLT3-ITD; patients with t(6;9) who receive HSCT have a more favorable outcome.
  MedlineGoogle Scholar
• 18. Panagopoulos I, Åman P, Fioretos T, Höglund M, Johansson B, Mitelman F. Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22). Genes Chromosomes Cancer 11(4), 256–262 (1994).
  Medline CASGoogle Scholar
• 19. Gamou T, Kitamura E, Hosoda F et al. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family. Blood 91(11), 4028–4037 (1998).
  Medline CASGoogle Scholar
• 20. Noort S, Zimmermann M, Reinhardt D et al. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM study group. Blood 132(15), 1584–1593 (2018). •• Showed that FUS-ERG-rearranged AML should be considered high-risk, whereas RUNX1-CBFA2T3-rearranged AML may benefit from stratification in the standard risk treatment.
  Medline CASGoogle Scholar
• 21. Tomizawa D, Yoshida M, Kondo T, Miyamura T, Taga T. Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases. Bone Marrow Transplant. 54(3), 393–401 (2019). •• Demonstrated that patients with t(16;21)(p11;q22)/FUS-ERG represent an extremely poor prognostic subgroup even with allo-HSCT during remission.
  Medline CASGoogle Scholar
• 22. Ismael O, Shimada A, Elmahdi S, Elshazley M. RUNX1 mutation associated with clonal evolution in relapsed pediatric acute myeloid leukemia with t(16;21)(p11;q22). Int. J. Hematol. 99(2), 169–174 (2014).
  Medline CASGoogle Scholar
• 23. Zerkalenkova E, Panfyorova A, Kazakova A et al. Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG. Ann. Hematol. 97(6), 977–988 (2018).
  Medline CASGoogle Scholar
• 24. Kong BX, Ida K, Ichikawa H et al. Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16; 21)(p11; q22) and identification of a novel transcript. Blood 90(3), 1192–1199 (1997).
  Medline CASGoogle Scholar
• 25. Imashuku S, Hibi S, Sako M, Lin Y, Tsunematsu Y. Hemophagocytosis by leukemic blasts in 7 acute myeloid leukemia cases with t(16;21)(p11;q22): common morphologic characteristics for this type of leukemia. Cancer 88(8), 1970–1975 (2000).
  Medline CASGoogle Scholar
• 26. Coenen EA, Zwaan CM, Reinhardt D et al. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Muenster AML-study group. Blood 122(15), 2704–2713 (2013). •• Demonstrated that pediatric t(8;16)(p11;p13) AML is a rare entity defined by a unique gene expression signature and distinct clinical features, with intermediate survival, in which spontaneous remissions occur in a subset of neonatal cases.
  Medline CASGoogle Scholar
• 27. Gomes Andrade F, Pereira E, Maria R et al. Identification of the MYST3-CREBBP fusion gene in infants with acute myeloid leukemia and hemophagocytosis. Brazilian J. Hematol. Hemotherapy 8(4), 291–297 (2016).
  Google Scholar
• 28. Hollink IHIM, van den Heuvel-Eibrink MM, Arentsen-Peters STCJM et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 118(13), 3645–3656 (2011). •• Identified NUP98/NSD1 fusion gene in young AML patients with distinct characteristics and dismal prognosis.
  Medline CASGoogle Scholar
• 29. Romana S, Radford-Weiss I, Ben Abdelali R et al. NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogénétique Hématologique. Leukemia 20(4), 696–706 (2006).
  Medline CASGoogle Scholar
• 30. Cerveira N, Correia C, Doria S et al. Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia. Leukemia 17(11), 2244–2247 (2003).
  Medline CASGoogle Scholar
• 31. Hara Y, Shiba N, Ohki K et al. Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome. Genes Chromosomes Cancer 56(5), 394–404 (2017).
  Medline CASGoogle Scholar
• 32. von Bergh ARM, van Drunen E, Van Wering ER et al. High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9. Genes Chromosomes Cancer 45(8), 731–739 (2006).
  Medline CASGoogle Scholar
• 33. Satake N, Maseki N, Nishiyama M et al. Chromosome abnormalities and MLL rearrangements in acute myeloid leukemia of infants. Leukemia 13(7), 1013–1017 (1999).
  Medline CASGoogle Scholar
• 34. Chi Y, Lindgren V, Quigley S, Gaitonde S. Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia. Arch. Pathol. Lab. Med. 132(11), 1835–1837 (2008).
  MedlineGoogle Scholar
• 35. Zwaan CM, Meshinchi S, Radich JP et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 102(7), 2387–2394 (2003).
  Medline CASGoogle Scholar
• 36. Akiki S, Dyer SA, Grimwade D et al. NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR. Genes Chromosomes Cancer 52(11), 1053–1064 (2013).
  Medline CASGoogle Scholar
• 37. Pigazzi M, Manara E, Bresolin S et al. MicroRNA-34b promoter hypermethylation induces CREB overexpression and contributes to myeloid transformation. Haematologica 98(4), 602–610 (2013).
  Medline CASGoogle Scholar
• 38. Ostronoff F, Othus M, Gerbing RB et al. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood 124(15), 2400–2408 (2014).
  Medline CASGoogle Scholar
• 39. Taketani T, Taki T, Nakamura T et al. High frequencies of simultaneous FLT3-ITD, WT1 and KIT mutations in hematological malignancies with NUP98-fusion genes. Leukemia 24(11), 1975–1977 (2010).
  Medline CASGoogle Scholar
• 40. Fasan A, Haferlach C, Alpermann T, Kern W, Haferlach T, Schnittger S. A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98-NSD1 fusion gene. Leukemia 27(1), 245–248 (2013).
  Medline CASGoogle Scholar
• 41. Thol F, Kölking B, Hollink IHI et al. Analysis of NUP98/NSD1 translocations in adult AML and MDS patients. Leukemia 27(3), 750–754 (2013).
  Medline CASGoogle Scholar
• 42. Masetti R, Togni M, Astolfi A et al. DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia. Oncotarget 4(10), 1712–1720 (2013).
  MedlineGoogle Scholar
• 43. Elgarten CW, Aplenc R. Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy. Curr. Opin. Pediatr. 32(1), 57–66 (2020).
  MedlineGoogle Scholar
• 44. Qin H, Malek S, Cowell JK, Ren M. Transformation of human CD34+ hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model. Oncogene 35(43), 5686–5691 (2016).
  Medline CASGoogle Scholar
• 45. Sandén C, Ageberg M, Petersson J, Lennartsson A, Gullberg U. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR. BMC Cancer 13, 440 (2013).
  MedlineGoogle Scholar
• 46. Harrison CJ, Hills RK, Moorman AV et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council treatment trials AML 10 and 12. J. Clin. Oncol. 28(16), 2674–2681 (2010).
  MedlineGoogle Scholar
• 47. Díaz-Beyá M, Labopin M, Maertens J et al. Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission. Br. J. Haematol. 189(5), 920–925 (2020).
  Medline CASGoogle Scholar
• 48. Kayser S, Hills RK, Luskin MR et al. Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. Haematologica 105(1), 161–169 (2020).
  Medline CASGoogle Scholar
• 49. Stone RM, Mandrekar SJ, Sanford BL et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl. J. Med. 377(5), 454–464 (2017).
  Medline CASGoogle Scholar
• 50. Jekarl WD, Kim M, Lim J et al. CD56 antigen expression and hemophagocytosis of leukemic cells in acute myeloid leukemia with t(16;21)(p11;q22). Int. J. Hematol. 92(2), 306–313 (2010).
  Medline CASGoogle Scholar
• 51. Marosi C, Bettelheim P, Geissler K et al. Acute monoblastic leukemia with erythrophagocytosis. Cancer Genet. Cytogenet. 54(1), 61–66 (1991).
  Medline CASGoogle Scholar
• 52. Bock J, Mochmann LH, Schlee C et al. ERG transcriptional networks in primary acute leukemia cells implicate a role for ERG in deregulated kinase signaling. PLoS ONE 8(1), e52872 (2013).
  Medline CASGoogle Scholar
• 53. Martens JHA, Mandoli A, Simmer F et al. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood 120(19), 4038–4048 (2012).
  Medline CASGoogle Scholar
• 54. Sotoca AM, Prange KHM, Reijnders B et al. The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia. Oncogene 35(15), 1965–1976 (2016). • Suggested that FUS-ERG acts as a transcriptional repressor of the retinoic acid signaling pathway and all-trans retinoic acid treatment triggers differentiation and thereby stops self-renewal.
  Medline CASGoogle Scholar
• 55. Masetti R, Vendemini F, Zama D, Biagi C, Gasperini P, Pession A. All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia. Expert Rev. Anticancer Ther. 12(9), 1191–1204 (2012).
  Medline CASGoogle Scholar
• 56. Yao S, Jianlin C, Yarong L et al. Donor-derived CD123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML. Front. Oncol. 9, 1358 (2019).
  Google Scholar
• 57. Wu X, Sulavik D, Roulston D, Lim M. Spontaneous remission of congenital acute myeloid leukemia with t(8;16)(p11;13). Pediatr. Blood Cancer 56(11), 331–332 (2011).
  MedlineGoogle Scholar
• 58. Diab A, Zickl L, Abdel-wahab O et al. Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leuk. Res. 37(1), 32–36 (2013).
  Medline CASGoogle Scholar
• 59. Barrett R, Marfleet L, Morash B et al. FISH identifies a KAT6A/CREBBP fusion caused by a cryptic insertional t(8;16) in a case of spontaneously remitting congenital acute myeloid leukemia with a normal karyotype. Pediatr. Blood Cancer 64(8) (2017).
  MedlineGoogle Scholar
• 60. Weintraub M, Kaplinsky C, Amariglio N et al. Spontaneous regression of congenital leukaemia with an 8;16 translocation. Br. J. Haematol. 111(2), 641–643 (2000).
  Medline CASGoogle Scholar
• 61. Díaz-Beyá M, Navarro A, Ferrer G et al. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. Leukemia 27(3), 595–603 (2013).
  Medline CASGoogle Scholar
• 62. Camos M, Esteve J, Jares P et al. Gene expression profiling of acute myeloid leukemia with rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res. 66(14), 6947–6955 (2006).
  Medline CASGoogle Scholar
• 63. Murati A, Gervais C, Carbuccia N et al. Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia 23(1), 85–94 (2009).
  Medline CASGoogle Scholar
• 64. Haferlach T, Kohlmann A, Klein H et al. AML with translocation t (8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia 23(5), 934–943 (2009).
  Medline CASGoogle Scholar
• 65. Baell JB, Leaver DJ, Hermans SJ et al. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature 560(7717), 253–257 (2018).
  Medline CASGoogle Scholar
• 66. Jaju RJ, Fidler C, Haas OA et al. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood 98(4), 1264–1268 (2001).
  Medline CASGoogle Scholar
• 67. Struski S, Lagarde S, Bories P et al. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis. Leukemia 31(3), 565–572 (2017). •• Demonstrated that NUP98-rearranged pediatric AML begins with epigenetic dysregulation, followed by mutations of critical hematopoietic transcription factors and activation of the FLT3 signalling pathway.
  Medline CASGoogle Scholar
• 68. Noort S, Wander P, Alonzo TA et al. The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. Haematologica doi:10.3324/haematol.2019.236745 (2020) (Epub ahead of print).
  Google Scholar
• 69. Shiba N, Ichikawa H, Taki T et al. NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer 52(7), 683–693 (2013).
  Medline CASGoogle Scholar
• 70. Xu H, Valerio DG, Eisold ME et al. NUP98 fusion proteins interact with the NSL and MLL1 complexes to drive leukemogenesis. Cancer Cell 30(6), 863–878 (2016).
  Medline CASGoogle Scholar
• 71. Bisio V, Zampini M, Tregnago C et al. NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group. Leukemia 31(4), 974–977 (2017). •• First study documenting in primary NUP98-NSD1-rearranged leukemia cells an altered spindle assembly checkpoint and an aberrant response to DNA damage.
  Medline CASGoogle Scholar
• 72. Lavallé V, Lemieux S, Boucher G et al. Identification of MYC mutations in acute myeloid leukemias with NUP98-NSD1 translocations. Leukemia 30(7), 1621–1624 (2016).
  MedlineGoogle Scholar
• 73. Cardin S, Bilodeau M, Roussy M et al. Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities. Blood Adv 3(21), 3307–3321 (2019). •• First study demonstrating that NUP98-KDM5A expression in human cord blood hematopoietic stem and progenitor cells is a potent inducer of maturation arrest and is associated with activation of JAK-STAT pathway, resulting in vulnerability to ruxolitinib, a clinically approved JAK2 inhibitor.
  Medline CASGoogle Scholar
• 74. Gruber TA, Larson Gedman A, Zhang J et al. An inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell 29(10), 1883–1889 (2012). •• Together with [70] detected for the first time CBFA2T3-GLIS2 fusion gene as driver in the initiation of AMKL in pediatric patients.
  Google Scholar
• 75. Thiollier C, Lopez CK, Gerby B et al. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J. Exp. Med. 209(11), 2017–2031 (2012). •• Together with [69] detected for the first time CBFA2T3-GLIS2 fusion gene as driver in the initiation of AMKL in pediatric patients.
  Medline CASGoogle Scholar
• 76. Masetti R, Bertuccio SN, Astolfi A et al. Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene. J. Hematol. Oncol. 10(1), 26 (2017). • Demonstrated that GANT61, a hedgehog pathway inhibitor, selectively inhibited proliferation of cell lines and primary cells harboring CBFA2T3-GLIS2 fusion.
  MedlineGoogle Scholar
• 77. Masetti R, Rondelli R, Fagioli F et al. Infants with acute myeloid leukemia treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica 2002/01 protocol have an outcome comparable to that of older children. Haematologica 99(8), 127–129 (2014).
  MedlineGoogle Scholar
• 78. Lopez CK, Noguera E, Stavropoulou V et al. Ontogenic changes in hematopoietic hierarchy determine pediatric specificity and disease phenotype in fusion oncogene–driven myeloid leukemia. Cancer Discov. 9(12), 1736–1753 (2019). •• Demonstrated that aggressive pediatric AMKL originates in fetal hematopoietic stem progenitor cells.
  Medline CASGoogle Scholar
• 79. Creutzig U, Dworzak MN, Zimmermann M et al. Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups. Pediatr. Blood Cancer 64(12) (2017).
  Google Scholar
• 80. Masetti R, Bertuccio SN, Pession A, Locatelli F. CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity. Br. J. Haematol. 184(3), 337–347 (2019).
  Medline CASGoogle Scholar
• 81. Thirant C, Ignacimouttou C, Lopez CK et al. ETO2-GLIS2 hijacks transcriptional complexes to drive cellular identity and self-renewal in pediatric acute megakaryoblastic leukemia. Cancer Cell 31(3), 452–465 (2017).
  Medline CASGoogle Scholar
• 82. Thirant C, Lopez C, Malinge S, Mercher T. Molecular pathways driven by ETO2-GLIS2 in aggressive pediatric leukemia. Mol. Cell. Oncol. 4(6), e1345351 (2017).
  MedlineGoogle Scholar
• 83. Eidenschink Brodersen L, Alonzo T, Menssen A et al. A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group. 30(10), 2077–2080 (2016).
  Google Scholar
• 84. Wen Q, Goldenson B, Silver SJ et al. Integrative screening approach identifies regulators of polyploidization and targets for acute megakaryocytic leukemia. Cell 150(3), 575–589 (2012).
  Medline CASGoogle Scholar
• 85. Wichmann C, Chen L, Heinrich M et al. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells. Cancer Res. 67(5), 2280–2289 (2007).
  Medline CASGoogle Scholar
• 86. Pan D, Li Y, Li Z, Wang Y, Wang P, Liang Y. Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with rapamycin. Leuk. Res. 36(6), 742–748 (2012).
  Medline CASGoogle Scholar
• 87. Agyeman A, Jha BK, Mazumdar T, Houghton JA. Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding. Oncotarget 5(12), 4492–4503 (2014).
  MedlineGoogle Scholar
• 88. Vasanth S, ZeRuth G, Kang HS, Jetten AM. Identification of nuclear localization, DNA binding, and transactivating mechanisms of krüppel-like zinc finger protein gli-similar 2 (GLIS2). J. Biol. Chem. 286(6), 4749–4759 (2011).
  Medline CASGoogle Scholar
• 89. Naiel A, Vetter M, Plekhanova O et al. A novel three-colour fluorescence in situ hybridization approach for the detection of t(7;12)(q36;p13) in acute myeloid leukaemia reveals new cryptic three way translocation t(7;12;16). Cancers (Basel) 5(1), 281–295 (2013).
  Medline CASGoogle Scholar
• 90. Park J, Kim M, Lim J et al. Three-way complex translocations in infant acute myeloid leukemia with t(7;12)(q36;p13): the incidence and correlation of a HLXB9 overexpression. Cancer Genet. Cytogenet. 191(2), 102–105 (2009).
  Medline CASGoogle Scholar
• 91. Tosi S, Kamel YM, Owoka T, Federico C, Truong TH, Saccone S. Paediatric acute myeloid leukaemia with the t(7;12)(q36;p13) rearrangement: a review of the biological and clinical management aspects. Biomark. Res. 3, 21 (2015).
  MedlineGoogle Scholar
• 92. Tosi S, Hughes J, Scherer SW et al. Heterogeneity of the 7q36 breakpoints in the t (7;12) involving ETV6 in infant leukemia. Genes Chromosomes Cancer 38(2), 191–200 (2003).
  Medline CASGoogle Scholar
• 93. Espersen ADL, Ha S, Hasle H, Abrahamsson J, Noren-nystr UJG. Acute myeloid leukemia (AML) with t(7;12)(q36;p13) is associated with infancy and trisomy 19: data from Nordic Society for Pediatric Hematology and Oncology (NOPHO-AML) and review of the literature. Genes Chromosomes Cancer 57(7), 359–365 (2018). •• Showed that t(7;12)(q36;13) is a unique subgroup of childhood AML with presentation before 2 years of age, with most cases being associated with +19.
  Medline CASGoogle Scholar
• 94. Webb DKH, Harrison G, Stevens RF, Gibson BG, Hann IM. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 98(6), 1714–1721 (2001).
  Medline CASGoogle Scholar
• 95. Harrison CJ, Hills RK, Moorman AV et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council treatment trials AML 10 and 12. J. Clin. Oncol. 28(16), 2674–2681 (2010).
  MedlineGoogle Scholar
• 96. Chessells JM, Harrison CJ, Kempski H et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. Leukemia 16(5), 776–784 (2002).
  Medline CASGoogle Scholar
• 97. Beverloo HB, Panagopoulos I, Isaksson M et al. Fusion of the homeobox gene HLXB9 and the ETV6 gene in infant acute myeloid leukemias with the t(7;12)(q36;p13). Cancer Res. 61(14), 5374–5377 (2001).
  Medline CASGoogle Scholar
• 98. Zhou F, Chen B. Acute myeloid leukemia carrying ETV6 mutations: biologic and clinical features. Hematology 23(9), 608–612 (2018).
  Medline CASGoogle Scholar
• 99. Ballabio E, Cantarella C, Federico C et al. Ectopic expression of the HLXB9 gene is associated with an altered nuclear position in t(7;12) leukaemias. Leukemia 23(6), 1179–1182 (2009).
  Medline CASGoogle Scholar
• 100. Tosi S, Harbott J, Teigler-schlegel A et al. t(7;12)(q36;p13), a new recurrent translocation involving ETV6 in infant leukemia. Genes Chromosomes Cancer 29(4), 325–332 (2000).
  Medline CASGoogle Scholar
• 101. Hirsch B, Alonzo TA, Gerbing RB et al. Abnormalities of 12p are associated with high-risk acute myeloid leukemia: a Children's Oncology Group report. Blood 122(21), 612 (2013). •• Showed that 12p is relatively rare in AML and that AML patients with 12p abnormalities have a poor prognosis.
  Google Scholar
• 102. Simmons HM, Oseth L, Nguyen P, Leary MO, Conklin KF, Hirsch B. Cytogenetic and molecular heterogeneity of 7q36/12p13 rearrangements in childhood AML. Leukemia 16(12), 2408–2416 (2002).
  Medline CASGoogle Scholar
• 103. Ward E, Desantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J. Clin. 64(2), 83–103 (2014).
  MedlineGoogle Scholar
• 104. Wildenhain S, Ruckert C, Röttgers S et al. Expression of cell–cell interacting genes distinguishes HLXB9/TEL from MLL-positive childhood acute myeloid leukemia. Leukemia 24(9), 1657–1660 (2010).
  Medline CASGoogle Scholar
• 105. Taketani T, Taki T, Sako M, Ishii T. MNX1-ETV6 fusion gene in an acute megakaryoblastic leukemia and expression of the MNX1 gene in leukemia and normal B cell lines. Cancer Genet. Cytogenet. 186(2), 115–119 (2008).
  Medline CASGoogle Scholar
• 106. Nagel S, Ehrentraut S, Meyer C, Kaufmann M, Drexler HG, MacLeod RAF. Oncogenic deregulation of NKL homeobox gene MSX1 in mantle cell lymphoma. Leuk. Lymphoma. 55(8), 1893–1903 (2014).
  Medline CASGoogle Scholar
• 107. Neufing PJ, Kalionis B, Horsfall DJ et al. Expression and localization of homeodomain proteins DLX4/HB9 in normal and malignant human breast tissues. Anticancer Res. 23(2B), 1479–1488 (2003).
  Medline CASGoogle Scholar
• 108. Almstrup K, Leffers H, Lothe RA et al. Improved gene expression signature of testicular carcinoma in situ. Int. J. Androl. 30(4), 292–302 (2007).
  Medline CASGoogle Scholar
• 109. Wilkens L, Jaggi R, Hammer C, Inderbitzin D, Giger O, von Neuhoff N. The homeobox gene HLXB9 is upregulated in a morphological subset of poorly differentiated hepatocellular carcinoma. Virchows Arch. 458(6), 697–708 (2011).
  Medline CASGoogle Scholar
• 110. El-Khazragy N, Ghozy S, Matbouly S et al. Interaction between 12p chromosomal abnormalities and Lnc–HOTAIR mediated pathway in acute myeloid leukemia. J. Cell. Biochem. 120(9), 15288–15296 (2019).
  Medline CASGoogle Scholar
• 111. de Rooij J, Beuling E, Fornerod M, Obulkasim A, Baruchel A, Trka J. ETV6 aberrations are a recurrent event in pediatric acute myeloid leukemia with poor clinical outcome. Blood 124(21), 1012 (2014).
  Google Scholar
• 112. Hernandez JM, Gonzalez MB, Garcia JL et al. Two cases of myeloid disorders and a t(8;12)(q12;p13). Haematologica 85(1), 31–34 (2000).
  Medline CASGoogle Scholar
• 113. Slater RM, Drunen E, Kroes WG et al. t(7;12)(q36;p13) and t(7;12)(q32;p13) – translocations involving ETV6 in children 18 months of age or younger with myeloid disorders. Leukemia 15(6), 915–920 (2001).
  Medline CASGoogle Scholar
• 114. Bertuccio SN, Boudia F, Cambot M et al. The pediatric acute leukemia fusion oncogene ETO2-GLIS2 increases self-renewal and alters differentiation in a human induced pluripotent stem cells–derived model. HemaSphere 4(1), e319 (2020). •• Demonstrated for the first time that induced pluripotent stem cells (iPSCs) could be useful for studying the early stages of fetal hematopoiesis of pediatric AML.
  MedlineGoogle Scholar